Red blood cell

Anticoagulation Trials

ACTIV IV ACUTE: Anti-thrombotics for Adults Hospitalized With COVID-19

  • Judith Hochman, MD
  • Matthew Neal, MD

ACTIV-4a (Acute/Inpatient) is a randomized, open label, adaptive platform trial to compare the effectiveness and safety of different antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients, including specific under-represented minority populations. The study aims to: determine the most effective antithrombotic strategy on the composite endpoint of death, deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, or other systemic arterial thrombosis; for increasing the days free of organ support and reducing death; to assess the safety through the major endpoint of major bleeding; to compare strategies on the endpoint of all-cause mortality.

For further information:

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-79

  • Jean M. Connors, MD
    PI (Brigham and Women’s Hospital)
  • Paul M. Ridker, MD
    Trial Chair (Brigham and Women’s Hospital)

The COVID-19 Outpatient Thrombosis Prevention Trial is a multi-center adaptive randomized double-blind placebo-controlled platform trial to compare the effectiveness of anti-coagulation with anti-platelet agents and with placebo to prevent thrombotic events in patients diagnosed with COVID-19 who have evidence of increased inflammation based on elevated D-dimer and hsCRP levels, yet are not admitted to hospital as COVID-19 related symptoms are currently stable. Participants will all be adults between 40 and 79 years who will be enrolled from approximately 100 facilities, such as emergency rooms and other settings where a physician is present to evaluate the patient for inclusion and exclusion criteria.